logo
Plus   Neg
Share
Email

Regeneron & Sanofi: Dupixent Approved For Severe Asthma Indication In EU

Dupixent, which is being developed jointly by Regeneron and Sanofi, is now approved in the European Union for use in adults and adolescents 12 years and older as an add-on maintenance treatment for severe asthma with type 2 inflammation. Dupixent is also approved in the EU for the treatment of adults with moderate-to-severe atopic dermatitis.

Dupixent was approved last year in the U.S. as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Textron Specialized Vehicles recalled 20,573 units of Gas-powered E-Z-GO, Cushman and Tracker brand off-road vehicles for possible fire hazard, a statement by the U.S. Consumer Product Safety Commission said. The company said starter generator wire can be improperly secured, allowing it to come into contact with the vehicle's exhaust that could cause a fire hazard. Delta Air Lines Inc. said Friday that it will invest $1 billion over the next decade to mitigate all greenhouse gas emissions from its global business, starting March 1, 2020. The company intends to become the first airline in the world to go carbon neutral. The airline said that over the next decade, it will spend $1 billion to drive innovation and advance clean-air travel technologies. Crown Castle International Corp. (REIT) (CCI) is currently gaining over 1% on Friday morning. Early this week, a U.S. District judge ruled in favor of Sprint and T-Mobile's long-pending $26 billion merger deal. The judge dismissed a lawsuit brought by a group of State Attorneys General. The deal is...
Follow RTT
>